{"entity": "publication", "iuid": "bad66d6da3a54ef5a318993521e66e90", "timestamp": "2026-09-30T23:42:19.207Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/bad66d6da3a54ef5a318993521e66e90.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/bad66d6da3a54ef5a318993521e66e90"}}, "title": "Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma.", "authors": [{"family": "Ramachandran", "given": "Mohanraj", "initials": "M"}, {"family": "Vaccaro", "given": "Alessandra", "initials": "A"}, {"family": "van de Walle", "given": "Tiarne", "initials": "T"}, {"family": "Georganaki", "given": "Maria", "initials": "M"}, {"family": "Lugano", "given": "Roberta", "initials": "R"}, {"family": "Vemuri", "given": "Kalyani", "initials": "K"}, {"family": "Kourougkiaouri", "given": "Despoina", "initials": "D"}, {"family": "Vazaios", "given": "Konstantinos", "initials": "K"}, {"family": "Hedlund", "given": "Marie", "initials": "M"}, {"family": "Tsaridou", "given": "Georgia", "initials": "G"}, {"family": "Uhrbom", "given": "Lene", "initials": "L"}, {"family": "Pietil\u00e4", "given": "Ilkka", "initials": "I"}, {"family": "Martikainen", "given": "Miika", "initials": "M"}, {"family": "van Hooren", "given": "Luuk", "initials": "L"}, {"family": "Olsson Bontell", "given": "Thomas", "initials": "T"}, {"family": "Jakola", "given": "Asgeir S", "initials": "AS"}, {"family": "Yu", "given": "Di", "initials": "D"}, {"family": "Westermark", "given": "Bengt", "initials": "B"}, {"family": "Essand", "given": "Magnus", "initials": "M"}, {"family": "Dimberg", "given": "Anna", "initials": "A"}], "type": "journal article", "published": "2023-06-12", "journal": {"title": "Cancer Cell", "issn": "1878-3686", "volume": "41", "issue": "6", "pages": "1134-1151.e10", "issn-l": "1535-6108"}, "abstract": "Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T cell infiltration. LIGHT/TNFSF14 can induce high endothelial venules (HEVs) and tertiary lymphoid structures (TLS), suggesting that its therapeutic expression could promote T cell recruitment. Here, we use a brain endothelial cell-targeted adeno-associated viral (AAV) vector to express LIGHT in the glioma vasculature (AAV-LIGHT). We found that systemic AAV-LIGHT treatment induces tumor-associated HEVs and T cell-rich TLS, prolonging survival in \u03b1PD-1-resistant murine glioma. AAV-LIGHT treatment reduces T cell exhaustion and promotes TCF1+CD8+ stem-like T cells, which reside in TLS and intratumoral antigen-presenting niches. Tumor regression upon AAV-LIGHT therapy correlates with tumor-specific cytotoxic/memory T cell responses. Our work reveals that altering vascular phenotype through vessel-targeted expression of LIGHT promotes efficient anti-tumor T cell responses and prolongs survival in glioma. These findings have broader implications for treatment of other immunotherapy-resistant cancers.", "doi": "10.1016/j.ccell.2023.04.010", "pmid": "37172581", "labels": [], "xrefs": [{"db": "pii", "key": "S1535-6108(23)00136-8"}], "notes": [], "created": "2026-09-23T07:28:24.576Z", "modified": "2026-09-23T07:28:24.597Z"}